Head-to-head evidence
rotigotine vs SER-252 (PEOZ-apomorphine)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
rotigotine · Neupro
Marketed by UCB
NCT00244387 · Phase 3 · completed
Although the registry reports a randomized, double-blind design with 506 participants, it lists no comparator arm, so the treatment cannot be evaluated against another treatment or placebo from the available record. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
SER-252 (PEOZ-apomorphine)
Developed by Serina Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07422675 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: rotigotine's landscape · SER-252 (PEOZ-apomorphine)'s landscape